Renub Research has announced its recent publication on “Global Cervical Cancer Screening Market & Patients, By Test Type (Pap Smear, HPV DNA, VIA) Forecast”. The report gives a comprehensive picture of Global Cervical Cancer Screening Market with available diagnostic test pursued by developed, developing and under-privilege countries. In addition volume of patients diagnosed with cervical cancer and their mortality rate is also mentioned in this report. As of now cervical cancer cases is rising globally, Asia and North America both have reported more than 90 Million cervical cancer cases for the year 2016.
Cervical cancer is malignant tumour of the cervix and affecting women all over the world. Cervical cancer is a disease that impacted patients after long period, early diagnosed and treatment of precancerous lesions is considered to be more effective in women who sequentially take part in screening programs. Pap smear test is used at large-scale screening technique in European countries; however, HPV test is steadily gaining accommodation.
Significant measures taken by government and public awareness initiatives have reinforced HPV testing and immunization. Moreover, growing acceptance of the HPV test especially in the untapped developing markets will deliver substantial growth performance.
In low-income countries, VIA (Visual inspection with acetic acid) is used as a screening for cervical cancer due to lower health infrastructure and fund PAP smear and HPV test is not viable in these countries. Over the next decades, new and effective screening (VIA test) and early treatment technique will be the elementary drivers of reduced death from cervical cancer. Many international NGOs have been establishing pilot programme and make technical details available to respective governments.
ASCO Published Worldwide Guidance for HPV Vaccination for Cervical Cancer Prevention
The American Society of Clinical Oncology (ASCO) has recently published recommendation and guidelines for human papillomavirus (HPV) vaccination for how to prevent cervical cancer. The guideline recommends 4 level resource setting: Basic, Limited, Enhanced and Maximal. The level includes countries financial resources and development of health system, infrastructure, health personnel and accessibility of services.
In geographic areas along with limited or basic resource settings, foremost focus on vaccinating girls aged 9 to 14.
All girl aged 15 years and older, recommended maximal and enhanced resource settings. If girl has received her first dose before age 15, then she may complete two-dose series and if not then she should take three doses.
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Follow us on LinkedIn: http://www.linkedin.com/company/renub-research